Synlogic SYBX
Synlogic FY 2024: revenue $8K, down 100%; diluted EPS −$1.92
- Form
- 10-K/A
- Filed
- Period
- Importance
- Routine
- Accession
- 0000950170-25-060786
- Document
- 10-K/A
- Exhibit 10.8
- Material contract
Key figures from this report
These are the numbers Synlogic reported for the year ended Dec 31, 2024, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Revenue$8K−100% from $3.4M in FY 202310-K income statement, on EDGAR
- Net income−$23.4MAgainst −$57.3M in FY 202310-K income statement, on EDGAR
- Diluted EPS−$1.92Against −$8.81 in FY 202310-K income statement, on EDGAR
- Cash and cash equivalents$18.9M−21% from $24.0M in FY 2023Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
- Cash from operations−$31.7MAgainst −$51.6M in FY 202310-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Matinas BioPharma Holdings MTNB public float $5M, Jun 30, 2025
- China Pharma Holdings CPHI public float $4M, Jun 30, 2025
- Soligenix SNGX public float $5M, Jun 30, 2025
- Target Group CBDY public float $5M, Jun 30, 2025
- Creative Medical Technology Holdings CELZ public float $5M, Jun 30, 2025
